1. Home
  2. SLVM vs AGIO Comparison

SLVM vs AGIO Comparison

Compare SLVM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$43.08

Market Cap

1.7B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.08

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
AGIO
Founded
1898
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SLVM
AGIO
Price
$43.08
$28.08
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$54.00
$38.88
AVG Volume (30 Days)
270.4K
1.3M
Earning Date
05-08-2026
04-29-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
N/A
EPS
3.24
N/A
Revenue
$3,351,000,000.00
$43,011,000.00
Revenue This Year
$0.93
$76.75
Revenue Next Year
$1.54
$170.73
P/E Ratio
$13.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.09
$22.24
52 Week High
$61.31
$46.00

Technical Indicators

Market Signals
Indicator
SLVM
AGIO
Relative Strength Index (RSI) 52.98 45.65
Support Level $41.08 $26.64
Resistance Level $44.05 $29.69
Average True Range (ATR) 1.52 1.34
MACD 0.19 -0.56
Stochastic Oscillator 70.28 32.88

Price Performance

Historical Comparison
SLVM
AGIO

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: